Table 2.

Summary of Adverse Events Reported in ≥2 Subjects, Regardless of Causality

			Vestipitant cohort
Preferred term, n (%)			1 (N = 6)	2 (N = 5)	3 (N = 6)	4 (N = 6)	5 (N = 6)	6 (N = 6)	7 (N = 6)
Infusion	Total (N = 55)	Placebo (N = 14)	12 mg/2 min	18 mg/2 min	24 mg/2 min	24 mg/1 min	24 mg/30 s	36 mg/30 s	48 mg/30 s
Subjects with any AE	31 (56)	8 (57)	5 (83)	5 (100)	4 (67)	3 (50)	1 (17)	3 (50)	2 (33)
Subject with any related AE	25 (45)	6 (43)	4 (67)	5 (100)	4 (67)	2 (33)	1 (17)	1 (17)	0
Infusion site pain	5 (9)	0	1 (17)	1 (20)	2 (33)	1 (17)	0	0	0
Infusion related reaction	5 (9)	0	3 (50)	1 (20)	0	0	0	0	1 (17)
Infusion site hematoma	5 (9)	2 (14)	0	1 (20)	2 (33)	0	0	0	0
Headache	5 (9)	1 (7)	1 (17)	1 (20)	1 (17)	1 (17)	0	0	0
Lethargy	4 (7)	0	0	2 (40)	0	0	0	2 (33)	0
Procedural dizziness	3 (5)	0	1 (17)	1 (20)	0	1 (17)	0	0	0
Somnolence	3 (5)	2 (14)	0	0	0	0	1 (17)	0	0
Dysgeusia	2 (4)	0	0	0	0	1 (17)	1 (17)	0	0
Infusion site discomfort	2 (4)	0	0	0	0	1 (17)	0	1 (17)	0
Myalgia	2 (4)	0	1 (17)	0	0	1 (17)	0	0	0
Upper respiratory tract infection	2 (4)	0	2 (33)	0	0	0	0	0	0
Abdominal pain	2 (4)	1 (7)	0	0	0	1 (17)	0	0	0